Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine and Oral Fluid Drug Testing for Federal Agencies, 35185-35187 [2024-09372]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 85 / Wednesday, May 1, 2024 / Notices
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Initial Review Group; Digestive Diseases and
Nutrition C Study Section.
Date: June 6–7, 2024.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: InterContinental Chicago Hotel, 505
North Michigan Avenue, Chicago, IL 60611
(In-person and Virtual).
Contact Person: Peter J. Kozel, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7009, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–4721,
kozelp@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: April 25, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–09322 Filed 4–30–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Synergy in Science: Innovations in
Autoimmune Disease Research and
Care
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This symposium is sponsored
by the National Institutes of Health
(NIH), Office of Research on Women’s
Health (ORWH), and the title of this
year’s symposium is ‘‘Synergy in
Science: Innovations in Autoimmune
Disease Research and Care.’’ The
symposium will discuss the
convergence of cutting-edge insights
and collaborative efforts in the realm of
autoimmune diseases.
DATES: The meeting will be held on May
15, 2024, from 1 to 5 p.m.
ADDRESSES: The meeting will be virtual.
Registration is available at https://
nih.zoomgov.com/webinar/register/WN_
jYi3sBFvToeHZJcfytw6GA#/registration.
The meeting is viewable on NIH
Videocast at https://videocast.nih.gov/
watch=54417; no registration is
required.
FOR FURTHER INFORMATION CONTACT: For
information concerning this meeting,
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
16:59 Apr 30, 2024
Jkt 262001
see the ORWH website, https://orwh.od.
nih.gov/about/newsroom/events/8thannual-vivian-w-pinn-symposium, or
contact Dr. Vicki Shanmugam, Director,
NIH Office of Autoimmune Disease
Research in the Office of Research on
Women’s Health, 6707 Democracy
Boulevard, Suite 400, Bethesda, MD
20817, telephone: 301–402–4179; email:
vicki.shanmugam@nih.gov.
SUPPLEMENTARY INFORMATION: This
Notice is in accordance with 42 U.S.C.
287d, of the Public Health Service Act,
as amended. The 8th Annual Vivian W.
Pinn Symposium honors the first fulltime Director of ORWH, Dr. Vivian
Pinn, and is held during National
Women’s Health Week. This event
serves as a critical forum for experts
across sectors to communicate and
collaborate for the advancement of
women’s health.
Providing the keynote address,
‘‘Understanding the Immunome: Past,
Present, and Future,’’ is Jane Buckner,
M.D., President of Benaroya Research
Institute.
The objectives of the symposium are:
• Drivers of Autoimmunity:
Understand the state of the science on
sex-differences in autoimmune diseases,
and what the future may hold for
interventions.
• NIH Research Frontiers: Explore
innovations arising from NIH’s
intramural research programs, driving
progress in autoimmune care through
rigorous scientific inquiry and
technological breakthroughs.
• Advocacy Accelerating Treatments:
Examine the synergy between patient
advocacy and scientific progress,
highlighting how collaborative efforts
expedite the development of novel
treatments for rare autoimmune
diseases.
• Research at the Bedside: Unravel
the complexities of autoimmune
diseases across the lifespan through
patient-centric bedside research
insights.
Interested individuals can register at:
https://nih.zoomgov.com/webinar/
register/WN_
jYi3sBFvToeHZJcfytw6GA#/registration.
More information about the speakers
and agenda can be found at https://
orwh.od.nih.gov/about/newsroom/
events/8th-annual-vivian-w-pinnsymposium.
This event is free.
Dated: April 24, 2024.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes
of Health.
[FR Doc. 2024–09345 Filed 4–30–24; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00153
Fmt 4703
Sfmt 4703
35185
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine and Oral
Fluid Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITFs) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines) using
Urine and the laboratories currently
certified to meet the standards of the
Mandatory Guidelines using Oral Fluid.
FOR FURTHER INFORMATION CONTACT:
Anastasia Flanagan, Division of
Workplace Programs, SAMHSA/CSAP,
5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240–276–
2600 (voice); Anastasia.Flanagan@
samhsa.hhs.gov (email).
SUPPLEMENTARY INFORMATION: The
Department of Health and Human
Services (HHS) publishes a notice
listing all HHS-certified laboratories and
Instrumented Initial Testing Facilities
(IITFs) in the Federal Register during
the first week of each month, in
accordance with Section 9.19 of the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and
Section 9.17 of the Mandatory
Guidelines using Oral Fluid. If any
laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace/drug-testing-resources/
certified-lab-list.
HHS separately notifies Federal
agencies of the laboratories and IITFs
currently certified to meet the standards
of the Mandatory Guidelines using
Urine and of the laboratories currently
SUMMARY:
E:\FR\FM\01MYN1.SGM
01MYN1
35186
Federal Register / Vol. 89, No. 85 / Wednesday, May 1, 2024 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
certified to meet the standards of the
Mandatory Guidelines using Oral Fluid.
The Mandatory Guidelines using
Urine were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); January 23,
2017 (82 FR 7920); and on October 12,
2023 (88 FR 70768).
The Mandatory Guidelines using Oral
Fluid were first published in the
Federal Register on October 25, 2019
(84 FR 57554) with an effective date of
January 1, 2020, and subsequently
revised in the Federal Register on
October 12, 2023 (88 FR 70814).
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
of Public Law 100–71 and allowed urine
drug testing only. The Mandatory
Guidelines using Urine have since been
revised, and new Mandatory Guidelines
allowing for oral fluid drug testing have
been published. The Mandatory
Guidelines require strict standards that
laboratories and IITFs must meet in
order to conduct drug and specimen
validity tests on specimens for Federal
agencies. HHS does not allow IITFs to
conduct oral fluid testing.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines using Urine and/
or Oral Fluid. An HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that the test facility has met minimum
standards. HHS does not allow IITFs to
conduct oral fluid testing.
HHS-Certified Laboratories Approved
to Conduct Oral Fluid Drug Testing
In accordance with the Mandatory
Guidelines using Oral Fluid effective
October 10, 2023 (88 FR 70814), the
following HHS-certified laboratories
meet the minimum standards to conduct
drug and specimen validity tests on oral
fluid specimens:
At this time, there are no laboratories
certified to conduct drug and specimen
validity tests on oral fluid specimens.
VerDate Sep<11>2014
16:59 Apr 30, 2024
Jkt 262001
HHS-Certified Instrumented Initial
Testing Facilities Approved to Conduct
Urine Drug Testing
In accordance with the Mandatory
Guidelines using Urine effective
February 1, 2024 (88 FR 70768), the
following HHS-certified IITFs meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
Dynacare*, 6628 50th Street NW,
Edmonton, AB Canada T6B 2N7,
780–784–1190 (Formerly: GammaDynacare Medical Laboratories)
HHS-Certified Laboratories Approved
to Conduct Urine Drug Testing
In accordance with the Mandatory
Guidelines using Urine effective
February 1, 2024 (88 FR 70768), the
following HHS-certified laboratories
meet the minimum standards to conduct
drug and specimen validity tests on
urine specimens:
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–
8989/800–433–3823 (Formerly:
Kroll Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130 (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing
Laboratories, Inc.)
Clinical Reference Laboratory, Inc., 8433
Quivira Road, Lenexa, KS 66215–
2802, 800–445–6917
Desert Tox, LLC, 5425 E Bell Rd, Suite
125, Scottsdale, AZ 85254, 602–
457–5411/623–748–5045
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044,
800–235–4890
Dynacare*, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4,
519–679–1630 (Formerly: GammaDynacare Medical Laboratories)
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS
66219, 913–888–3927/800–873–
8845 (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center
for Laboratory Services, a Division
of LabOne, Inc.)
Laboratory Corporation of America,
1225 NE 2nd Ave., Portland, OR
97232, 503–413–5295/800–950–5295
(Formerly: Legacy Laboratory Services
Toxicology MetroLab)
Laboratory Corporation of America
Holdings, 7207 N Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387
PO 00000
Frm 00154
Fmt 4703
Sfmt 4703
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–
4986 (Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 1904 TW Alexander
Drive, Research Triangle Park, NC
27709, 919–572–6900/800–833–
3984 (Formerly: LabCorp
Occupational Testing Services, Inc.,
CompuChem Laboratories, Inc.;
CompuChem Laboratories, Inc., A
Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem
Laboratories, Inc., A Member of the
Roche Group)
Laboratory Corporation of America
Holdings, 1120 Main Street,
Southaven, MS 38671, 866–827–
8042/800–233–6339 (Formerly:
LabCorp Occupational Testing
Services, Inc.; MedExpress/National
Laboratory Center)
MedTox Laboratories, Inc., 402 W
County Road D, St. Paul, MN 55112,
651–636–7466/800–832–3244
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
Laboratory, 1 Veterans Drive,
Minneapolis, MN 55417, 612–725–
2088. Testing for Veterans Affairs
(VA) Employees Only
Omega Laboratories, Inc.*, 2150
Dunwin Drive, Unit 1 & 2,
Mississauga, ON, Canada L5L 5M8,
289–919–3188
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA
91311, 800–328–6942 (Formerly:
Centinela Hospital Airport
Toxicology Laboratory)
Phamatech, Inc., 15175 Innovation
Drive, San Diego, CA 92128, 888–
635–5840
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
610–631–4600/877–642–2216
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline
Bio-Science Laboratories)
US Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson
St., Fort George G. Meade, MD
20755–5235, 301–677–7085.
Testing for Department of Defense
(DoD) Employees Only
* The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories continued under
E:\FR\FM\01MYN1.SGM
01MYN1
Federal Register / Vol. 89, No. 85 / Wednesday, May 1, 2024 / Notices
DOT authority. The responsibility for
conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory as meeting
the minimum standards of the current
Mandatory Guidelines published in the
Federal Register. After receiving DOT
certification, the laboratory will be
included in the monthly list of HHScertified laboratories and participate in
the NLCP certification maintenance
program. DOT established this process
in July 1996 (61 FR 37015) to allow
foreign laboratories to participate in the
DOT drug testing program.
Anastasia D. Flanagan,
Public Health Advisor, Division of Workplace
Programs.
[FR Doc. 2024–09372 Filed 4–30–24; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF THE INTERIOR
Fish and Wildlife Service
[FWS–R4–ES–2024–N026;
FXES11140400000–245–FF04E00000]
Endangered Species; Recovery Permit
Applications
Fish and Wildlife Service,
Interior.
ACTION: Notice of receipt of permit
applications; request for comments.
AGENCY:
We, the U.S. Fish and
Wildlife Service, have received
applications for permits to conduct
activities intended to enhance the
propagation or survival of endangered
species under the Endangered Species
Act. We invite the public and local,
State, Tribal, and Federal agencies to
comment on these applications. Before
issuing any of the requested permits, we
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
will take into consideration any
information that we receive during the
public comment period.
DATES: We must receive written data or
comments on the applications by May
31, 2024.
ADDRESSES: Reviewing Documents:
Submit requests for copies of
applications and other information
submitted with the applications to
Karen Marlowe (see FOR FURTHER
INFORMATION CONTACT). All requests and
comments should specify the
applicant’s name and application
number (e.g., Mary Smith,
ESPER0001234).
Submitting Comments: If you wish to
comment, you may submit comments by
one of the following methods:
• Email (preferred method):
permitsR4ES@fws.gov. Please include
your name and return address in your
email message. If you do not receive a
confirmation from the U.S. Fish and
Wildlife Service that we have received
your email message, contact us directly
at the telephone number listed in FOR
FURTHER INFORMATION CONTACT.
• U.S. mail: U.S. Fish and Wildlife
Service Regional Office, Ecological
Services, 1875 Century Boulevard,
Atlanta, GA 30345 (Attn: Karen
Marlowe, Permit Coordinator).
FOR FURTHER INFORMATION CONTACT:
Karen Marlowe, Permit Coordinator, via
telephone at 404–679–7097 or via email
at karen_marlowe@fws.gov. Individuals
in the United States who are deaf,
deafblind, hard of hearing, or have a
speech disability may dial 711 (TTY,
TDD, or TeleBraille) to access
telecommunications relay services.
Individuals outside the United States
should use the relay services offered
within their country to make
international calls to the point-ofcontact in the United States.
SUPPLEMENTARY INFORMATION: We, the
U.S. Fish and Wildlife Service, invite
review and comment from the public
and local, State, Tribal, and Federal
agencies on applications we have
received for permits to conduct certain
activities with endangered and
threatened species under section
10(a)(1)(A) of the Endangered Species
Act of 1973, as amended (ESA; 16
Permit application No.
Applicant
Species
Location
ES117405–5 ...............
Tennessee
Valley Authority;
Knoxville,
TN.
Tricolored bat (Perimyotis subflavus) ........
Alabama, Arkansas,
Georgia, Kentucky,
Mississippi, North
Carolina, Tennessee, and Virginia.
VerDate Sep<11>2014
16:59 Apr 30, 2024
Jkt 262001
PO 00000
Frm 00155
Fmt 4703
Sfmt 4703
35187
U.S.C. 1531 et seq.), and our regulations
in the Code of Federal Regulations
(CFR) at 50 CFR part 17. Documents and
other information submitted with the
applications are available for review,
subject to the requirements of the
Privacy Act of 1974, as amended (5
U.S.C. 552a), and the Freedom of
Information Act (5 U.S.C. 552).
Background
With some exceptions, the ESA
prohibits take of listed species unless a
Federal permit is issued that authorizes
such take. The definition of ‘‘take’’ in
the ESA includes hunting, shooting,
harming, wounding, or killing, and also
such activities as pursuing, harassing,
trapping, capturing, or collecting.
A recovery permit issued by us under
section 10(a)(1)(A) of the ESA
authorizes the permittee to take
endangered or threatened species while
engaging in activities that are conducted
for scientific purposes that promote
recovery of species or for enhancement
of propagation or survival of species.
These activities often include the
capture and collection of species, which
would result in prohibited take if a
permit were not issued. Our regulations
implementing section 10(a)(1)(A) of the
ESA for these permits are found at 50
CFR 17.22 for endangered wildlife
species, 50 CFR 17.32 for threatened
wildlife species, 50 CFR 17.62 for
endangered plant species, and 50 CFR
17.72 for threatened plant species.
Permit Applications Available for
Review and Comment
The ESA requires that we invite
public comment before issuing these
permits. Accordingly, we invite local,
State, Tribal, and Federal agencies, and
the public to submit written data, views,
or arguments with respect to these
applications. The comments and
recommendations that will be most
useful and likely to influence agency
decisions are those supported by
quantitative information or studies.
Proposed activities in the following
permit requests are for the recovery and
enhancement of propagation or survival
of the species in the wild.
Activity
Presence/
probable
absence
surveys.
E:\FR\FM\01MYN1.SGM
Type of take
Enter hibernacula or
maternity roost
caves, capture
with mist nets or
harp traps, handle,
identify, collect hair
samples, band,
radio tag, light tag,
wing punch, and
release.
01MYN1
Permit action
Renewal and
amendment
]]>Agencies
[Federal Register Volume 89, Number 85 (Wednesday, May 1, 2024)]
[Notices]
[Pages 35185-35187]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-09372]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of HHS-Certified Laboratories and Instrumented
Initial Testing Facilities Which Meet Minimum Standards To Engage in
Urine and Oral Fluid Drug Testing for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
Federal agencies of the laboratories and Instrumented Initial Testing
Facilities (IITFs) currently certified to meet the standards of the
Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and the laboratories currently
certified to meet the standards of the Mandatory Guidelines using Oral
Fluid.
FOR FURTHER INFORMATION CONTACT: Anastasia Flanagan, Division of
Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240-276-2600 (voice);
[email protected] (email).
SUPPLEMENTARY INFORMATION: The Department of Health and Human Services
(HHS) publishes a notice listing all HHS-certified laboratories and
Instrumented Initial Testing Facilities (IITFs) in the Federal Register
during the first week of each month, in accordance with Section 9.19 of
the Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and Section 9.17 of the Mandatory
Guidelines using Oral Fluid. If any laboratory or IITF certification is
suspended or revoked, the laboratory or IITF will be omitted from
subsequent lists until such time as it is restored to full
certification under the Mandatory Guidelines.
If any laboratory or IITF has withdrawn from the HHS National
Laboratory Certification Program (NLCP) during the past month, it will
be listed at the end and will be omitted from the monthly listing
thereafter.
This notice is also available on the internet at https://www.samhsa.gov/workplace/drug-testing-resources/certified-lab-list.
HHS separately notifies Federal agencies of the laboratories and
IITFs currently certified to meet the standards of the Mandatory
Guidelines using Urine and of the laboratories currently
[[Page 35186]]
certified to meet the standards of the Mandatory Guidelines using Oral
Fluid.
The Mandatory Guidelines using Urine were first published in the
Federal Register on April 11, 1988 (53 FR 11970), and subsequently
revised in the Federal Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); January 23, 2017 (82 FR 7920); and on October
12, 2023 (88 FR 70768).
The Mandatory Guidelines using Oral Fluid were first published in
the Federal Register on October 25, 2019 (84 FR 57554) with an
effective date of January 1, 2020, and subsequently revised in the
Federal Register on October 12, 2023 (88 FR 70814).
The Mandatory Guidelines were initially developed in accordance
with Executive Order 12564 and section 503 of Public Law 100-71 and
allowed urine drug testing only. The Mandatory Guidelines using Urine
have since been revised, and new Mandatory Guidelines allowing for oral
fluid drug testing have been published. The Mandatory Guidelines
require strict standards that laboratories and IITFs must meet in order
to conduct drug and specimen validity tests on specimens for Federal
agencies. HHS does not allow IITFs to conduct oral fluid testing.
To become certified, an applicant laboratory or IITF must undergo
three rounds of performance testing plus an on-site inspection. To
maintain that certification, a laboratory or IITF must participate in a
quarterly performance testing program plus undergo periodic, on-site
inspections.
Laboratories and IITFs in the applicant stage of certification are
not to be considered as meeting the minimum requirements described in
the HHS Mandatory Guidelines using Urine and/or Oral Fluid. An HHS-
certified laboratory or IITF must have its letter of certification from
HHS/SAMHSA (formerly: HHS/NIDA), which attests that the test facility
has met minimum standards. HHS does not allow IITFs to conduct oral
fluid testing.
HHS-Certified Laboratories Approved to Conduct Oral Fluid Drug Testing
In accordance with the Mandatory Guidelines using Oral Fluid
effective October 10, 2023 (88 FR 70814), the following HHS-certified
laboratories meet the minimum standards to conduct drug and specimen
validity tests on oral fluid specimens:
At this time, there are no laboratories certified to conduct drug
and specimen validity tests on oral fluid specimens.
HHS-Certified Instrumented Initial Testing Facilities Approved to
Conduct Urine Drug Testing
In accordance with the Mandatory Guidelines using Urine effective
February 1, 2024 (88 FR 70768), the following HHS-certified IITFs meet
the minimum standards to conduct drug and specimen validity tests on
urine specimens:
Dynacare*, 6628 50th Street NW, Edmonton, AB Canada T6B 2N7, 780-784-
1190 (Formerly: Gamma-Dynacare Medical Laboratories)
HHS-Certified Laboratories Approved to Conduct Urine Drug Testing
In accordance with the Mandatory Guidelines using Urine effective
February 1, 2024 (88 FR 70768), the following HHS-certified
laboratories meet the minimum standards to conduct drug and specimen
validity tests on urine specimens:
Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-361-
8989/800-433-3823 (Formerly: Kroll Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236,
804-378-9130 (Formerly: Kroll Laboratory Specialists, Inc., Scientific
Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories,
Inc.)
Clinical Reference Laboratory, Inc., 8433 Quivira Road, Lenexa, KS
66215-2802, 800-445-6917
Desert Tox, LLC, 5425 E Bell Rd, Suite 125, Scottsdale, AZ 85254, 602-
457-5411/623-748-5045
DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800-
235-4890
Dynacare*, 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519-679-
1630 (Formerly: Gamma-Dynacare Medical Laboratories)
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655,
662-236-2609
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS
66219, 913-888-3927/800-873-8845 (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division
of LabOne, Inc.)
Laboratory Corporation of America, 1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295/800-950-5295 (Formerly: Legacy Laboratory Services
Toxicology MetroLab)
Laboratory Corporation of America Holdings, 7207 N Gessner Road,
Houston, TX 77040, 713-856-8288/800-800-2387
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ
08869, 908-526-2400/800-437-4986 (Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America Holdings, 1904 TW Alexander Drive,
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984 (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group)
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671, 866-827-8042/800-233-6339 (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center)
MedTox Laboratories, Inc., 402 W County Road D, St. Paul, MN 55112,
651-636-7466/800-832-3244
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088.
Testing for Veterans Affairs (VA) Employees Only
Omega Laboratories, Inc.*, 2150 Dunwin Drive, Unit 1 & 2, Mississauga,
ON, Canada L5L 5M8, 289-919-3188
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311, 800-328-6942 (Formerly: Centinela Hospital Airport Toxicology
Laboratory)
Phamatech, Inc., 15175 Innovation Drive, San Diego, CA 92128, 888-635-
5840
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403,
610-631-4600/877-642-2216 (Formerly: SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science Laboratories)
US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755-5235, 301-677-7085. Testing for
Department of Defense (DoD) Employees Only
* The Standards Council of Canada (SCC) voted to end its Laboratory
Accreditation Program for Substance Abuse (LAPSA) effective May 12,
1998. Laboratories certified through that program were accredited to
conduct forensic urine drug testing as required by U.S. Department of
Transportation (DOT) regulations. As of that date, the certification of
those accredited Canadian laboratories continued under
[[Page 35187]]
DOT authority. The responsibility for conducting quarterly performance
testing plus periodic on-site inspections of those LAPSA-accredited
laboratories was transferred to the U.S. HHS, with the HHS' NLCP
contractor continuing to have an active role in the performance testing
and laboratory inspection processes. Other Canadian laboratories
wishing to be considered for the NLCP may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory as meeting the minimum
standards of the current Mandatory Guidelines published in the Federal
Register. After receiving DOT certification, the laboratory will be
included in the monthly list of HHS-certified laboratories and
participate in the NLCP certification maintenance program. DOT
established this process in July 1996 (61 FR 37015) to allow foreign
laboratories to participate in the DOT drug testing program.
Anastasia D. Flanagan,
Public Health Advisor, Division of Workplace Programs.
[FR Doc. 2024-09372 Filed 4-30-24; 8:45 am]
BILLING CODE 4162-20-P
